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detection of a relevant number of cancers 
that would not have otherwise become 
clinically apparent in the subject’s life-
time.4 Two components of overdiagnosis 
bias in lung cancer screening are rec-
ognized.5 First, the detection of slowly 
growing lung cancers with low probabil-
ity of malignant progression6 and, sec-
ond, the detection of cancers in subjects 
who would have had low probability of 
dying of a given type of cancer in their 
lifetime because of competing causes of 
death. The latter component is particu-
larly relevant in elderly heavy smokers 
and former smokers in consideration of 
the frequency of cardiovascular disease. 
Theoretically, at least three approaches 
can be adopted to study overdiagnosis 
in lung cancer screening: the epidemio-
logical one (see below), the imaging-
based one, which entails measurement 
of tumour doubling time reflecting local 
growth capability,7 and the pathological 
one, which is based on the characteriza-
tion of structural and biomarkers fea-
tures of tumor aggressiveness.
In general, overdiagnosis can be 
estimated in randomized clinical trials 
(RCTs) by comparing the cumulative 
cancer incidence in the screened ver-
sus the unscreened groups at the end 
of a long follow-up period, typically 
at least 5–10 years, after conclusion 
of study period and in absence of any 
screening in the control arm.8 In the 
absence of overdiagnosis the ratio of 
cumulative cancer incidence between 
screened and unscreened group should 
be 1, whereas any excess of lung cancer 
cases in the screened group can be con-
sidered as expression of overdiagnosis. 
Such an estimate of overdiagnosis is 
not yet possible in the NLST because 
of the short follow-up after the end of 
the study. Moreover, we would like to 
underline that subjects in the control 
group of NLST received chest radio-
graph annually2 and the possible overdi-
agnosis bias related to chest radiograph 
ray screening is unknown. We are con-
fident that results from RCTs should 
enable in the future a better assessment 
of overdiagnosis, which is an important 
potential harm of lung cancer screen-
ing with LDCT. In particular, we are 
of the opinion that a quantitative esti-
mate of overdiagnosis can be expected, 
in due time, from European RCTs, 
like Nederalnds Luevens Longkanker 
Screeningonderzoek (NELSON)9 and 
ITALUNG1 in which no screening test 
has been offered to subjects random-
ized to the control group.
For the present, in our opinion, 
the higher incidence at baseline as 
compared with subsequent screening 
rounds in ITALUNG1 and NLST2 tri-
als can be explained by lead time and 
should not considered per se a proof of 
overdiagnosis.5 
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In Response:
We thank Dr. Takiguchi and 
 colleagues for their comments on our 
article reporting the final results con-
cerning cancer detection and lesion 
management in the arm undergoing low-
dose computed tomography (LDCT) 
screening of the ITALUNG trial.1 To 
explain the higher detection rate of lung 
cancers at baseline LDCT screening 
round as compared with the three sub-
sequent annual repeat LDCT screening 
rounds observed in our study and in the 
National Lung Screening Trial (NLST) 
in the United States,2 they hypothesized 
that indolent cancers tend to accumulate 
preferentially without presenting symp-
toms at baseline, leading to a higher rate 
of overdiagnosis, than during subse-
quent screening rounds, a phenomenon 
known to occur in breast cancer screen-
ing with mammography.3
Overdiagnosis is defined as the 
possibility that screening determines 
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and to alter the substrate specificity 
of the mutated EZH2 in diffuse large 
B-cell lymphoma and follicular lym-
phoma. Importantly, lymphomas har-
boring these mutations in the EZH2 
gene can be successfully targeted by 
a potent, highly selective, S-adenosyl-
methionine-competitive, small-molecu-
lar inhibitor of EZH2 methyltransferase 
activity, that is, GSK126, in in vitro and 
in vivo models.4
Although recent integrative 
genomic analyses identified recurrent 
mutations of SCLC, such as the cAMP-
response element binding protein 
(CREB) binding protein (CREBBP), 
E1A binding protein p300 (EP300), 
and mixed-lineage leukemia (MLL) 
genes that encode histone modifiers, as 
well as the inactivation of tumor pro-
tein p53 (TP53) and retinoblastoma 
1 (RB1), mutations of the EZH2 gene 
have not yet been identified. In addition 
to the report by Peifer et al.,5 our analy-
sis of 35 patients diagnosed with SCLC 
failed to identify mutations of the EZH2 
gene in the SET domain.
In conclusion, we feel that further 
studies should be focused on the identi-
fication of mutations of the EZH2 gene, 
and if any are found, it should be clarified 
which of the overexpressed or mutated 
EZH2 genes most intensely promote 
SCLC tumorigenesis. Furthermore, it 
should be  elucidated which of these 
alterations can be successfully targeted 
for patients with SCLC. 
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To the Editor:
I read the article by Hubaux et al.1 
entitled “EZH2 promotes E2F-driven 
SCLC tumorigenesis through modula-
tion of apoptosis and cell-cycle regula-
tion” with much interest. In their study, 
the authors indicated that the stable 
down-regulation of the enhancer of 
zeste homolog 2 (EZH2) gene by short 
hairpin RNA modulates apoptosis and 
the cell cycle, which results in a reduc-
tion of the viability of small-cell lung 
cancer (SCLC) cell lines, and concluded 
that EZH2 can be a potential therapeu-
tic target for SCLC. Indeed, EZH2 is 
known to be targeted by Polycomb 
repressor complex 2 inhibitors, that is, 
S-adenosyl-homocysteine hydrolase 
inhibitor 3-deazaneplanocin A.2
Several reports suggested that 
EZH2 is overexpressed at the protein 
level in various types of solid tumors, 
including lung cancer, and its overex-
pression correlates with a poor prog-
nosis in patients with resected lung 
cancer.3 Additionally, somatic muta-
tions within two residues in the cata-
lytic SET domain of the EZH2 gene 
(Y641 and A677) were identified to 
have increased H3K27 trimethylation 
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In Response:
We thank Dr. Toyokawa and col-
leagues for their interest and for their 
thoughtful comments regarding our 
article demonstrating the importance 
of EZH2 in small-cell lung cancer 
(SCLC) tumorigenesis.1 Their letter to 
the Editor reiterates that EZH2 overex-
pression occurs in several cancer types 
and that it correlates with poor progno-
sis in lung cancer patients. Importantly, 
they also discuss the role of muta-
tions in the catalytic SET domain as 
a mechanism of EZH2 activation in 
lymphomas, for which potent inhibi-
tors have been shown to have thera-
peutic efficacy in vivo. They reaffirm 
EZH2 as an attractive therapeutic target 
given the prominence of its activation in 
SCLC. However, EZH2 mutations were 
not detected in a recent SCLC study 
(N = 29), nor in Toyokawa’s own cohort 
of SCLCs (N=35), raising the question 
of how EZH2 becomes aberrantly acti-
vated in SCLC.2
We further investigated pub-
lic data to detect EZH2 SET domain 
mutations in SCLC. None were iden-
tified in the NCI-H209 SCLC cell 
line sequence, in 42 SCLC exome 
sequences,3 or in 121 SCLCs with 
EZH2 mutation status in the COSMIC 
database. It is apparent that unlike 
other cancer types, mutations are not 
a common mechanism of EZH2 acti-
vation in SCLC. Furthermore, analy-
sis of data from two recent studies 
on SCLC tumors and cell lines from 
